Dell rises premarket; Tyson Foods, Nordstrom fall
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
Goldman Sachs sidelined on Tyson Foods (TSN) as 1Q miss shows deterioration in profitability
February 7, 2023 7:54 AM ESTGoldman Sachs downgraded Tyson Foods (NYSE: TSN) to a Neutral rating (From BUY) and cut the price target on the stock to $66.00 (from $91.00) following the food companys 1Q23 earnings report. The results revealed a sharp deterioration in profitability across the organization, most notably in Chicken, undermining confidence that the cumulative effect of recent operational and strategic changes could sustainability improve margins and earnings for the... More
AbbVie (ABBV) looks to new drugs to boost sales following Humira competition - WSJ
February 6, 2023 11:17 AM ESTAbbVie (NYSE: ABBV) is looking towards its new drugs to replace Humiria now that its blockbuster immune-disease therapy is facing lower-priced competition, the Wall Street Journal said Monday.
The WSJ said that the drugmaker's Chief Executive, Richard Gonzalez, revealed the company is turning to a pair of next-generation successors to reload the billions of dollars in sales that will be lost.
In... More
